galactose has been researched along with isavuconazole in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Box, H; Felton, TW; Goodwin, J; Hope, WW; Johnson, A; Livermore, J; McEntee, L; Whalley, S | 1 |
| Hope, WW; Katragkou, A; Kovanda, LL; Moradi, PW; Petraitiene, R; Petraitis, V; Strauss, GE; Walsh, TJ | 1 |
| Bonate, P; Desai, A; Hope, WW; Kovanda, LL; Petraitiene, R; Petraitis, V; Walsh, TJ | 1 |
| Bassetti, M; Bouza, E | 1 |
| Hope, WW; Kolamunnage-Dona, R; Kovanda, LL; Lee, M; Maertens, J; Neely, M | 1 |
| Hope, WW; Hussain, K; Kovanda, LL; Maung, BBW; McCarthy, MW; Petraitiene, R; Petraitis, V; Sekhon, NK; Shaikh, N; Walsh, TJ; Zaw, MH | 1 |
| Ader, F; Aguado, JM; Akova, M; Arendrup, MC; Arikan-Akdagli, S; Barnes, RA; Beigelman-Aubry, C; Blot, S; Bouza, E; Brüggemann, RJM; Buchheidt, D; Cadranel, J; Castagnola, E; Chakrabarti, A; Cornely, OA; Cuenca-Estrella, M; Denning, DW; Dimopoulos, G; Fortun, J; Gangneux, JP; Garbino, J; Groll, AH; Heinz, WJ; Herbrecht, R; Heussel, CP; Kibbler, CC; Klimko, N; Kullberg, BJ; Lagrou, K; Lange, C; Lass-Flörl, C; Lehrnbecher, T; Lewis, RE; Löffler, J; Lortholary, O; Maertens, J; Marchetti, O; Meis, JF; Munoz, P; Pagano, L; Ribaud, P; Richardson, M; Roilides, E; Ruhnke, M; Sanguinetti, M; Sheppard, DC; Sinkó, J; Skiada, A; Ullmann, AJ; Vehreschild, MJGT; Verweij, PE; Viscoli, C; Warris, A | 1 |
| Böll, B; Böttiger, BW; Cornely, OA; Dusse, F; Eichenauer, DA; Fuchs, F; Hallek, M; Jung, N; Klein, F; Kochanek, M; Koehler, P; Persigehl, T; Rybniker, J; Shimabukuro-Vornhagen, A | 1 |
1 review(s) available for galactose and isavuconazole
| Article | Year |
|---|---|
Invasive mould infections in the ICU setting: complexities and solutions.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; beta-Glucans; Critical Illness; Galactose; Humans; Immunocompromised Host; Intensive Care Units; Invasive Fungal Infections; Lung Diseases, Fungal; Mannans; Mucor; Mucormycosis; Nitriles; Opportunistic Infections; Pyridines; Respiratory System; Triazoles; Voriconazole | 2017 |
2 trial(s) available for galactose and isavuconazole
| Article | Year |
|---|---|
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Topics: Animals; Antifungal Agents; Aspergillus; Disease Models, Animal; Drug Monitoring; Female; Galactose; Humans; Invasive Pulmonary Aspergillosis; Mannans; Microbial Sensitivity Tests; Models, Theoretical; Monte Carlo Method; Nitriles; Pyridines; Rabbits; Triazoles | 2016 |
Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
Topics: Adult; Aged; Biomarkers; Drug Monitoring; Female; Galactose; Humans; Invasive Fungal Infections; Invasive Pulmonary Aspergillosis; Logistic Models; Male; Mannans; Middle Aged; Nitriles; Proportional Hazards Models; Pyridines; Survival Analysis; Treatment Outcome; Triazoles | 2017 |
5 other study(ies) available for galactose and isavuconazole
| Article | Year |
|---|---|
Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.
Topics: Antifungal Agents; Area Under Curve; Aspergillus fumigatus; Bioreactors; Diffusion Chambers, Culture; Drug Resistance, Fungal; Galactose; Humans; Mannans; Microbial Sensitivity Tests; Models, Biological; Models, Statistical; Nitriles; Pulmonary Alveoli; Pyridines; Triazoles | 2016 |
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Topics: Animals; Antifungal Agents; Aspergillus fumigatus; Bronchoalveolar Lavage Fluid; Female; Galactose; Invasive Pulmonary Aspergillosis; Mannans; Nitriles; Pyridines; Rabbits; Triazoles | 2016 |
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Topics: Animals; Antifungal Agents; Combined Modality Therapy; Echinocandins; Female; Galactose; Glucans; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung; Mannans; Micafungin; Nitriles; Pyridines; Rabbits; Triazoles | 2017 |
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
Topics: Antibodies, Fungal; Antifungal Agents; Aspergillosis; Aspergillus; Biopsy; Bronchoalveolar Lavage; Disease Management; Early Diagnosis; Flucytosine; Galactose; Humans; Immunocompromised Host; Immunologic Tests; Invasive Pulmonary Aspergillosis; Itraconazole; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mannans; Microbial Sensitivity Tests; Myelodysplastic Syndromes; Nitriles; Pyridines; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2018 |
COVID-19 associated pulmonary aspergillosis.
Topics: Aged; Antifungal Agents; Bronchoalveolar Lavage Fluid; Coronavirus Infections; COVID-19; Female; Galactose; Germany; Hemorrhage; Hospitals, Teaching; Humans; Intensive Care Units; Lung Diseases; Male; Mannans; Metapneumovirus; Middle Aged; Nitriles; Pandemics; Paramyxoviridae Infections; Pneumonia, Viral; Pulmonary Aspergillosis; Pyridines; Respiratory Distress Syndrome; Retrospective Studies; Thorax; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2020 |